In the United States, cholangiocarcinoma, or bile duct cancer, is relatively rare, although its incidence is growing for reasons experts have yet to identify. Because of its rarity, research into it has been scarce. But a Mount Sinai researcher has now identified five distinct classes of cholangiocarcinoma, each with a unique genetic signature and tumor microenvironment.